



Fig. 1



BEST AVAILABLE COPY

Fig. 2




BEST AVAILABLE COPY

E1/E3-minus Ad5


Fig. 3

40 pfu/cell 10 pfu/cell not infected




E1/E3-minus Ad5

Fig. 4



BEST AVAILABLE COPY

Fig. 5
not infected 20 pfu/cell



257RDB

U2OS

BEST AVAILABLE COPY

YB-1



MCF-Adr


181RDB

257RDB


U2OS

HeLa


Fig. 6



WT-AD5



dl520



dl119/1131




Fig. 7




Fig. 9




Fig. 10

Control:
No Daunorubicin

Daunorubicin:
40 ng/ml

30
10
C
30
10
C





Fig. 11

Control:
No Daunorubicin

Daunorubicin:
40 ng/ml







Fig. 12



BEST AVAILABLE COPY

Fig. 13

5×10^8 dl520






Fig. 15





Fig. 16

Wildtype Adenovirus



Xvir03




Fig. 17





Fig. 18A



BEST AVAILABLE COPY

Fig. 18B

Not infected 20 pfu Ad312 5 pfu Xvir03




Fig. 19

**Northern Blot Analysis of E2 gene
expression in Ad312 infected cells**







Fig. 20 Northern Blot Analysis of E2 gene expression in infected cells




XvirPSJL1
Fig. 21





HeLa cells infected with
different MOIs of dl520

Fig. 23



BEST AVAILABLE COPY





Fig. 24

BEST AVAILABLE COPY




U373 cells infected with 10 pfu
dl520/cell after incubation with
5 μ M Irinotecan for 24 hours

Fig. 26




Southern Blot Analysis

Fig. 27
U373 cells infected with 10 pfu dl520/cell
After incubation for 24 hours with
increasing concentrations of Trichostatin




Southern Blot Analysis

Fig. 28
FACS analysis: CAR expression of U373 cells after
incubation with Trichostatin for 24 hours



Oncolytic effect of dl520 in U373 cells in combination
with Irinotecan and Trichostatin

Fig. 29



E1B55k-region:

ORF = 2019 – 3506 bp

***BfrI* – cleavage site = 3534 bp**

3'UTR = 3507 – 4107 bp

E1B55k ORF

E1B55k 3'UTR

1 bp

5300 bp

Bfr I(3534)

Fig. 30

Fig. 31

5'tgaggtaactgaaatgtgtggcggtggcttaagggtggaaagaatataag
gtgggggtttagttgtatctgttttgtcagcaggcccgccatgagc
accaactcgtttgtatgaaagcattgtgagctcatattgacaacgcgcattggcc
catggccgggggtgcgtcagaatgtgtacccattgtggatggcattggatggcc
gtcctgcccggcaaactctactaccattgtacccgtgtggaaacgcgc
ttggagactgcaggccctccggcccgcttcagccgcgtcagccaccggcccg
ggatttgtgactgtactttgtcgttgcgttgcaggcacttccgt
tcatcccccgcgtgacaaatgtcgttgcgttgcgttgc
ccggaaacttaatgtcgttgcgttgcgttgcgttgc
ccctgaaggcttcctcccaatgcggttaaaacataaaaaacag
actcttttgtggatttggatcaagcaagtcgttgcgttgc




Fig. 32